RA
SYRE icon

Royce & Associates’s Spyre Therapeutics SYRE Stock Holding History

Royce & Associates’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.6M Buy
+51,789
New +$3.78M 0.04% 510

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Royce & Associates's SYRE Position: Q2 2026 in Review

Royce & Associates opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 51,789 shares worth $4.6M. The stake represents 0.04% of the portfolio and ranks #510 among its holdings.

265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Royce & Associates held 51,789 shares of Spyre Therapeutics worth $4.6M as of Q2 2026.
  • Spyre Therapeutics was a new Royce & Associates position in Q2 2026.
  • Spyre Therapeutics made up 0.04% of Royce & Associates's portfolio in Q2 2026, its #510 holding.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.